GRPR and breast cancer: Other groups developed and characterized 99mTc-labeled BBN-folate conjugates (99mTc-BBN-folate) aiming at combining the targeting capabilities of BBN, directed toward GRPR, and folate, which targets folate receptors (such as FRα) commonly overexpressed in breast cancer cells.